Comment from Biotechnology Innovation Organization
AnonymousAnalysis pending
See attached file(s)
Attachments
- BIO Comment Letter - FDA-2026-D-6539 - Quantitative Systems Pharmacology (QSP)-Based Dose Selection for MABEL in FIH Trials (PDF)
- BIO Comment Letter - FDA-2026-D-6539 - Quantitative Systems Pharmacology (QSP)-Based Dose Selection for MABEL in FIH Trials (DOCX)
- BIO Line Item Comments - FDA-2026-D-6539 - Quantitative Systems Pharmacology (QSP)-Based Dose Selection for MABEL in FIH Trials (PDF)
- BIO Line Item Comments - FDA-2026-D-6539 - Quantitative Systems Pharmacology (QSP)-Based Dose Selection for MABEL in FIH Trials (XLSX)